Search / Trial NCT06234306

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · Jan 29, 2024

Trial Information

Current as of October 09, 2024

Recruiting

Keywords

Small Bowel Adenocarcinoma Messenger Rna Dna T Cell Receptor Sequencing

Description

Small bowel adenocarcinoma (SBA), an orphan cancer, has annual diagnoses of 12,070 in the USA and 100 in Denmark. Despite its rarity, patient management should prioritize evidence-based care, but large trials are not feasible, leading to data scarcity and suboptimal care. As a result, SBA is treated like colorectal cancer, yet its prognosis is worse, indicating this parallel approach is insufficient. The grasp on SBAs molecular landscape is limited compared to prevalent cancers. Scant mutational profiling studies, suggest SBA is a heterogeneous disease where subsets resemble other gastroint...

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years
  • Exclusion criteria:
  • Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\&
  • Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.

About Copenhagen University Hospital At Herlev

Copenhagen University Hospital at Herlev is a leading academic medical center in Denmark, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous studies aimed at improving patient outcomes and advancing medical knowledge. With a strong commitment to ethical standards and patient safety, Copenhagen University Hospital at Herlev collaborates with researchers, healthcare professionals, and industry partners to explore new treatment modalities and enhance the standard of care across various medical fields.

Locations

Aarhus N, , Denmark

Copenhagen ø, , Denmark

Herlev, , Denmark

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0